[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366386-105":59,"doc-detail-366386-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","analysis-of-the-prognostic-and-immune-role-of-mcm6-in-pan-cancer-and-experimental-validation-in-lung-adenocarcinoma-cells","Analysis of the Prognostic and Immune Role of MCM6 in Pan-Cancer and Experimental Validation in Lung Adenocarcinoma Cells","","Mini-chromosome maintenance protein 6 (MCM6), implicated in DNA replication initiation, is evaluated as a potential prognostic and immune-related biomarker across pan-cancer, with focused experimental validation in lung adenocarcinoma. Pan-cancer bioinformatics integrates multi-database analyses of expression, DNA methylation, immune infiltration, and immunotherapy response, building a prognostic risk signature using WGCNA and LASSO Cox models. MCM6 is highly expressed in many tumors, correlating with immune cell infiltration and poor outcomes, while functional assays in vitro and xenograft studies show that MCM6 knockdown suppresses proliferation, invasion, migration, and tumor growth.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/analysis-of-the-prognostic-and-immune-role-of-mcm6-in-pan-cancer-and-experimental-validation-in-lung-adenocarcinoma-cells/366386/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/analysis-of-the-prognostic-and-immune-role-of-mcm6-in-pan-cancer-and-experimental-validation-in-lung-adenocarcinoma-cells/366386.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of studying MCM6 in this work?","Question",{"text":113,"@type":114},"To determine whether MCM6 can serve as a prognostic marker across multiple cancers and to clarify its immune-related role, followed by experimental verification in lung adenocarcinoma cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the prognostic risk signature for LUAD constructed?",{"text":118,"@type":114},"Using WGCNA and LASSO Cox regression with cell cycle genes related to MCM6 (MrCCGs) to build a risk signature, then validating its predictive performance for lung adenocarcinoma prognosis.",{"name":120,"@type":111,"acceptedAnswer":121},"What effects did MCM6 knockdown show in lung adenocarcinoma models?",{"text":122,"@type":114},"MCM6 knockdown inhibited proliferation, invasion, and migration of A549 and H1299 cells, blocked G1 phase progression in A549 cells, and suppressed xenograft tumor growth in nude mice.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366386,1791046862,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAnalysis of the prognostic and immune role of MCM6 in pancancer and experimental validation in lung adenocarcinoma cells  \nMinghua Liao1,2,6, Chunyu Li2,3,6, Jun Lv4, Rui Yang5, Jun Li2, KeWu2,3, Jiayi Zhang2,3, Qian Zhu2,3, Yingchang Shi2,3 & Xianming Zhang2􀀍  \nMini-chromosome maintenance protein 6 (MCM6), a member of the DNA replication initiation complex, is considered a potential prognostic marker for multiple tumors. However, the biological role of MCM6 has not been reported in pan-cancer. In present study, a pan-cancer analysis of MCM6 was performed using multiple databases and online websites. The relationship between MCM6 and DNA methylation, prognosis, immune infiltration and immunotherapy response was investigated. Weighted gene co-expression network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) Cox regression models were performed to construct prognostic risk signature for lung adenocarcinoma (LUAD) based on MCM6-related cell cycle genes (MrCCGs) . Meanwhile, the biological function of MCM6 in lung adenocarcinoma was further verified through in vivo and in vitro experiments. MCM6 is highly expressed and is a prognostic risk factor in most tumors. MCM6 expression is significantly associated with the infiltration of immune cells (especially MDSCs) in a variety of tumors. The risk signature based on MrCCGs can reliably predict the prognosis of LUAD (AUC = 0.739). Immunohistochemical staining showed that the expression of MCM6 is higher in lung adenocarcinoma tissues compared with para-cancer tissues and is associated with the poor prognosis of lung adenocarcinoma patients. In vitro, MCM6 knockdown inhibited proliferation, invasion, and migration of A549 and H1299 cells, and blocked the G1 phase of theA549 cell cycle. In vivo, knockdown of MCM6 inhibited the growth of xenograft tumors in nude mice. The study suggests that MCM6 maybe a potential prognostic and immunological biomarker in many cancers.  \nKeywords MCM6, Pan-cancer, Prognosis, Immune cell infiltration, Lung adenocarcinoma  \nOver recent decades, significant advancements in cancer treatment have been made through the integration of surgery, chemoradiotherapy, targeted therapy, and immunotherapy. However, despite these strides, many critical challenges remain unresolved, contributing to persistently low five-year survival rates for most cancer patients1. For patients with advanced cancer, whether it is chemotherapy, targeted therapy or immunotherapy, primary or secondary drug resistance will eventually lead to treatment failure2. Given the transient efficacy of therapies targeting a single molecule, it is imperative to identify new pharmacologically actionable targets. Expanding the repertoire of such targets could refine and enhance combination therapy strategies, ultimately improving outcomes for cancer patients.  \nTumor progression are driven by several key mechanisms, including continuous cell cycle activation, suppression of cell death, enhancement of invasion and metastasis, and modulation of both the tumor microenvironment and immune responses3. DNA replication, a pivotal process within the cell cycle, is intricately governed by the temporal and spatial expression changes and structural functionalities of various oncogenes and tumor suppressor genes4. Mini-chromosome maintenance proteins (MCMs) are crucial for genome replication  \n1The First People’s Hospital of Qingzhen City, Guiyang 551400, Guizhou, China. 2Department of Respiratory and Critical Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China. 3School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou 550004, China. 4Jinan Maternity and Child Care Hospital, Jinan 250001, Shandong, China. 5Department of Internal Medicine, Guiyang First People’s Hospital, Guiyang, Guizhou 550004, China. 6These authors contributed equally to this wor","cbCaisM97Nk10b4f","https://ap.wps.com/l/cbCaisM97Nk10b4f","pdf",4879838,"English","# Key Objective and Background\n# Pan-Cancer Bioinformatic Analysis\n## Prognostic Risk Signature Construction\n## Associations With DNA Methylation and Immune Infiltration\n# Experimental Validation in Lung Adenocarcinoma\n## Histology and Prognostic Correlation\n## In Vitro Functional Assays\n## In Vivo Xenograft Experiments\n# Conclusions and Implications","[{\"question\":\"What is the main purpose of studying MCM6 in this work?\",\"answer\":\"To determine whether MCM6 can serve as a prognostic marker across multiple cancers and to clarify its immune-related role, followed by experimental verification in lung adenocarcinoma cells.\"},{\"question\":\"How was the prognostic risk signature for LUAD constructed?\",\"answer\":\"Using WGCNA and LASSO Cox regression with cell cycle genes related to MCM6 (MrCCGs) to build a risk signature, then validating its predictive performance for lung adenocarcinoma prognosis.\"},{\"question\":\"What effects did MCM6 knockdown show in lung adenocarcinoma models?\",\"answer\":\"MCM6 knockdown inhibited proliferation, invasion, and migration of A549 and H1299 cells, blocked G1 phase progression in A549 cells, and suppressed xenograft tumor growth in nude mice.\"}]","Analysis of the Prognostic and Immune Role of MCM6 in Pan-Cancer and Experimental Validation in Lung Adenocarcinoma Cells | PDF",1790165134,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7052128b891c4a28b29920ee51cc6e65.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb340b7328430783ff159e6908a6845.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a49fd773b7ab48e7ceb6eb2500452d12.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d19615454fe264216c834fd6181efab.webp",980,1287]